EQL in-license seven products for Denmark
EQL Pharma has today purchased seven (7) licenses, of which five (5) are exclusive, for products on the Danish market. The licenses already have marketing authorizations in Denmark. "These are niche generics that complement our portfolio well and fit into our strategy for the Nordic region and Denmark," says Christer Fåhraeus, CEO of EQL Pharma. The total turnover in the markets where these products compete is slightly more than 50mDKK (2020). All products are prescription-only and have between one and three active competitors, excluding EQL.The sales start is expected in EQL Pharma’s first